Melanoma/Skin Cancer News

Half of patients with relapsed or refractory solid tumors achieved objective response to an infusion of IMA203, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

More than 80% of therapies tested in phase 3 oncology trials did not demonstrate clinically meaningful benefit in extending survival, according to results of a study published in JNCCN — Journal of the National Comprehensive Cancer Network.

A cyclic, 5-day fasting-mimicking diet appeared safe and showed potential to improve outcomes among patients on anticancer therapy for different tumor types, according to study results published in Cancer Discovery.

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.

Approvals of BRAF-targeted therapies and immune checkpoint inhibitors have greatly expanded the melanoma treatment landscape during the past decade, according to a speaker at Chemotherapy Foundation Symposium.

A higher rate of metastasis and death occurred in those with cutaneous squamous cell carcinomas with lymphovascular invasion, according to a study.

According to a new study, immune checkpoint inhibitor-induced myocarditis is highly associated with arrhythmias and ECG findings including new conduction blocks, decreased voltage and repolarization abnormalities.

Lower overall mortality, but not melanoma-specific mortality, was associated with melanoma diagnosed through routine skin checks, according to a study.

Localized Merkel cell carcinoma tumors with a primary site in the neck and scalp were associated with the highest 5-year probability of mortality, according to a study.

The Society for Immunotherapy of Cancer announced the inaugural class of Fellows of the Academy of Immuno-Oncology.